I2I
SCLN

Insight 2811 Inc’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Insight 2811 Inc’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-60,000
Closed -$304K – 101
2013
Q3 		$304K Sell
60,000
-5,000
-8% -$27.8K 0.15% 92
2013
Q2 		$322K Buy
+65,000
New +$309K 0.18% 98

Other funds holding SCLN

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Insight 2811 Inc's SCLN Position: Q4 2013 in Review

Insight 2811 Inc sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2013, closing a stake of 60,000 shares — an estimated $304K sold.

Insight 2811 Inc first reported a position in SCLN in Q2 2013 and held it in 2 quarters. The position peaked at $322K in Q2 2013. 100 funds tracked by Wall St. Rank hold SCLN as of Q4 2013.

  • Insight 2811 Inc reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Insight 2811 Inc sold 60,000 Sciclone Pharmaceuticals Inc shares in Q4 2013, an estimated $304K.
  • Insight 2811 Inc first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • Insight 2811 Inc's Sciclone Pharmaceuticals Inc position peaked at $322K in Q2 2013.
  • 100 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2013.

Based on Insight 2811 Inc's 13F filing for Q4 2013, filed 4 Feb 2014.